An open-label, non-comparative, treatment protocol for the use of BAY 43-9006 (sorafenib) in patients with advanced renal cell carcinoma
Phase of Trial: Phase III
Latest Information Update: 25 Aug 2011
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 25 Aug 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 25 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.